NO763344L - - Google Patents

Info

Publication number: NO763344L
Authority: NO; Norway
Prior art keywords: hepatitis; antigen; virus; antibody; antibodies
Prior art date: 1975-10-01

Application number

NO763344A

Other languages

English (en)

Norwegian (no)

Inventor

E Shaw

Original Assignee

Ortho Diagnostics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-10-01

Filing date

1976-09-30

Publication date

1977-04-04

1976-09-30 Application filed by Ortho Diagnostics filed Critical Ortho Diagnostics

1977-04-04 Publication of NO763344L publication Critical patent/NO763344L/no

Links

239000000427 antigen Substances 0.000 claims description 51
102000036639 antigens Human genes 0.000 claims description 49
108091007433 antigens Proteins 0.000 claims description 49
238000000034 method Methods 0.000 claims description 46
241000509391 A-2 plaque virus Species 0.000 claims description 44
208000002672 hepatitis B Diseases 0.000 claims description 25
208000005252 hepatitis A Diseases 0.000 claims description 22
101710132601 Capsid protein Proteins 0.000 claims description 20
238000006243 chemical reaction Methods 0.000 claims description 20
239000000463 material Substances 0.000 claims description 14
241000282412 Homo Species 0.000 claims description 8
206010019799 Hepatitis viral Diseases 0.000 claims description 6
208000024891 symptom Diseases 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
230000001939 inductive effect Effects 0.000 claims description 5
201000001862 viral hepatitis Diseases 0.000 claims description 5
230000037029 cross reaction Effects 0.000 claims description 3
238000001962 electrophoresis Methods 0.000 claims description 2
241000700605 Viruses Species 0.000 description 30
210000002966 serum Anatomy 0.000 description 29
239000002245 particle Substances 0.000 description 21
208000006454 hepatitis Diseases 0.000 description 17
231100000283 hepatitis Toxicity 0.000 description 17
239000011162 core material Substances 0.000 description 15
210000001519 tissue Anatomy 0.000 description 14
238000001514 detection method Methods 0.000 description 11
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 10
238000012360 testing method Methods 0.000 description 8
241000282577 Pan troglodytes Species 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000007788 liquid Substances 0.000 description 7
229960005486 vaccine Drugs 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
241000700721 Hepatitis B virus Species 0.000 description 5
230000003053 immunization Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000005755 formation reaction Methods 0.000 description 4
238000002649 immunization Methods 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
238000004448 titration Methods 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
208000034657 Convalescence Diseases 0.000 description 3
101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
239000008272 agar Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000012808 pre-inoculation Methods 0.000 description 3
230000000644 propagated effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
241000709721 Hepatovirus A Species 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
230000036541 health Effects 0.000 description 2
238000000760 immunoelectrophoresis Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000002356 single layer Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
241000428198 Lutrinae Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
241000282579 Pan Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
101100070137 Seriola quinqueradiata hbab gene Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000004523 agglutinating effect Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000007771 core particle Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000000003 hoof Anatomy 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000004383 yellowing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Hematology (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO763344A 1975-10-01 1976-09-30 NO763344L (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US05/618,644 US4100267A (en)	1975-10-01	1975-10-01	Method of detecting hepatitis B core antigen and antibody

Publications (1)

Publication Number	Publication Date
NO763344L true NO763344L (fr)	1977-04-04

Family

ID=24478533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO763344A NO763344L (fr)	1975-10-01	1976-09-30

Country Status (10)

Country	Link
US (1)	US4100267A (fr)
JP (1)	JPS5244230A (fr)
AU (1)	AU1807776A (fr)
BE (1)	BE846822A (fr)
DE (1)	DE2644493A1 (fr)
DK (1)	DK439576A (fr)
FR (1)	FR2326205A1 (fr)
NL (1)	NL7610853A (fr)
NO (1)	NO763344L (fr)
SE (1)	SE7610839L (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4241175A (en) *	1978-12-18	1980-12-23	Merck & Co., Inc.	Assay for hepatitis B core antibody
US6270955B1 (en)	1978-12-22	2001-08-07	Biogen, Inc.	Pharmaceutical compositions and methods for producing antibodies to hepatitis b virus and kits and methods for detecting antibodies to hepatitis b virus
US4464474A (en) *	1980-07-09	1984-08-07	Connaught Laboratories Limited	Non-A, non-B hepatitis assay and vaccine
US5866383A (en) *	1982-11-30	1999-02-02	The United States Of America As Represented By The Department Of Health And Human Services	In vitro ligation of foreign DNA into large eukaryotic viruses
US4547367A (en) *	1983-12-20	1985-10-15	The United States Of America As Represented By The Department Of Health And Human Services	Hepatitis B core antigen vaccine
US4547368A (en) *	1983-12-20	1985-10-15	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Hepatitis B core antigen vaccine made by recombinant DNA
US4752567A (en) *	1984-06-21	1988-06-21	Janssen Pharmaceutica N.V.	Method of visualizing individual submicroscopic metal particles
GB8604985D0 (en) *	1986-02-28	1986-04-09	Unilever Plc	Precipitated silicas
JPH085804B2 (ja) *	1988-04-28	1996-01-24	財団法人化学及血清療法研究所	Ａ型及びｂ型肝炎混合アジュバントワクチン
DE4422238C2 (de) *	1994-06-24	1996-05-30	Behringwerke Ag	Verfahren zur Isolierung einer Antigenpräparation
CN1500140A (zh) *	2001-03-28	2004-05-26	上海晶泰生物技术有限公司	用于测试多种待分析物的装置及方法

1975
- 1975-10-01 US US05/618,644 patent/US4100267A/en not_active Expired - Lifetime
1976
- 1976-09-23 AU AU18077/76A patent/AU1807776A/en not_active Expired
- 1976-09-29 DK DK439576A patent/DK439576A/da unknown
- 1976-09-30 BE BE171143A patent/BE846822A/fr unknown
- 1976-09-30 NL NL7610853A patent/NL7610853A/xx not_active Application Discontinuation
- 1976-09-30 SE SE7610839A patent/SE7610839L/xx unknown
- 1976-09-30 FR FR7629413A patent/FR2326205A1/fr not_active Withdrawn
- 1976-09-30 NO NO763344A patent/NO763344L/no unknown
- 1976-10-01 DE DE19762644493 patent/DE2644493A1/de active Pending
- 1976-10-01 JP JP51117354A patent/JPS5244230A/ja active Pending

Also Published As

Publication number	Publication date
DE2644493A1 (de)	1977-04-14
DK439576A (da)	1977-04-02
AU1807776A (en)	1978-04-06
US4100267A (en)	1978-07-11
BE846822A (fr)	1977-03-30
SE7610839L (sv)	1977-04-02
JPS5244230A (en)	1977-04-07
FR2326205A1 (fr)	1977-04-29
NL7610853A (nl)	1977-04-05

Publication	Publication Date	Title
Lee et al.	1994	Prevalence of human astrovirus serotypes in the Oxford region 1976–92, with evidence for two new serotypes
Mockett et al.	1981	Comparative studies with an enzyme‐linked immunosorbent assay (ELISA) for antibodies to avian infectious bronchitis virus
JP4625215B2 (ja)	2011-02-02	Ｎｓ１糖タンパク質を用いるフラビウイルスの早期検出
Chau et al.	1993	Detection of IgA class antibody to hepatitis E virus in serum samples from patients with hepatitis E virus infection
Dimmock	1969	New virus-specific antigens in cells infected with influenza virus
Kalimo et al.	1977	Solid-phase radioimmunoassay of human immunoglobulin M and immunoglobulin G antibodies against herpes simplex virus type 1 capsid, envelope, and excreted antigens
Zhang et al.	2002	Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non‐A,‐B, and‐C acute hepatitis
Maeno et al.	1970	Developmental sequence and intracellular sites of synthesis of three structural protein antigens of influenza A2 virus
CN101226196A (zh)	2008-07-23	一种检测ii型登革病毒ns1抗原的免疫诊断试剂盒
World Health Organization	1977	Advances in viral hepatitis: report of the WHO Expert Committee on Viral Hepatitis [meeting held in Geneva from 11 to 16 October 1976]
NO763344L (fr)	1977-04-04
Itoh et al.	1957	The infection of chimpanzees with ECHO viruses
CN101726593B (zh)	2012-10-17	一种检测登革病毒ns1抗原的免疫诊断试剂盒及其应用
Sinha et al.	1984	Purification and serological detection of mycoplasmalike organisms from plants affected by peach eastern X-disease
Fenton et al.	1991	Identification of cattle infected with bovine virus diarrhoea virus using a monoclonal antibody capture ELISA
Pillot et al.	1987	Immunological characterization of a viral agent involved in epidemic and sporadic non-A, non-B hepatitis
Marshall et al.	1990	Rapid detection of polyomavirus BK by a shell vial cell culture assay
Kistner et al.	2007	The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans
Lipton et al.	1963	Human coproantibody against polioviruses
Zuckerman et al.	1970	Antigens and viruses in acute hepatitis
CN102898517B (zh)	2014-06-04	抗西尼罗河病毒的非结构蛋白1的抗体及其应用
Chan et al.	1985	Comparison of serodiagnosis of group B coxsackievirus infections by an immunoglobulin M capture enzyme immunoassay versus microneutralization
CN118501446A (zh)	2024-08-16	一种检测坦布苏病毒抗体的间接elisa试剂盒及坦布苏病毒e蛋白结构域iii的应用
Robertson et al.	1992	Serological approaches to distinguish immune response to hepatitis A vaccine and natural infection
Stevens et al.	1969	Rapid identification of viruses by indirect immunofluorescence: standardization and use of antiserum pool to nine respiratory viruses